Skip to content

Placemark Investments, Inc.: ELD position timeline

Available 13F reports, 13D and 13G stakes and each Form 3, 4 and 5 line of Placemark Investments, Inc. on ELD, newest first. How the timeline and the estimate are built.

Placemark Investments, Inc. held 4,900 ELD shares at 2014-12-31 per its 13F-HR filed 2015-02-17.

the latest 13F is the newest step

  1. period ended2014-12-31
    13F 4,900 shares
    Change vs previous 13F +203 shares

    <0.01% of the 13F portfolio, value $205,000.

    13F-HR 0001315726-15-000001 filed by Placemark Investments, Inc.
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  2. period ended2014-09-30
    13F 4,697 shares
    Change vs previous 13F +4,697 shares

    <0.01% of the 13F portfolio, value $211,000.

    13F-HR 0001315726-14-000007 filed by Placemark Investments, Inc.
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  3. period ended2013-12-31
    13F 0 shares
    Change vs previous 13F -12,057 shares

    13F-HR 0001315726-14-000003 filed by Placemark Investments, Inc.
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

    Exited: the 13F for this period no longer lists the position.

  4. period ended2013-09-30
    13F 12,057 shares
    Change vs previous 13F -25,606 shares

    0.01% of the 13F portfolio, value $568,000.

    13F-HR 0001315726-13-000008 filed by Placemark Investments, Inc.
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  5. period ended2013-06-30
    13F 37,663 shares
    Change vs previous 13F not available

    0.04% of the 13F portfolio, value $1,810,000.

    13F-HR 0001315726-13-000006 filed by Placemark Investments, Inc.
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).